Big Cannabis Is Resetting, Expanding And Shuffling The Deck

Curaleaf Expects Strong Q4 Growth After Portfolio Reset

Curaleaf Holdings (TSX: CURA) (OTCQX: CURLF) reported Tuesday that it expects fourth-quarter revenue, excluding discontinued businesses, to exceed expectations and prior guidance, rising 4% sequentially and 1% year over year to at least $330 million.

The cannabis operator anticipates an adjusted gross margin of roughly 48.5% for the fourth quarter, excluding discontinued businesses, and approximately 50% for the full fiscal year 2025. Full fourth-quarter and full-year results are expected in early March.

Chairman and CEO Boris Jordan said the company shuttered its hemp business following tighter federal THC limits and exited Missouri after determining continued investment there was not justified.

“Having completed this reset initiative at the end of Q4, we’re closing the year on a high note with a solid foundation in place to drive renewed momentum and performance in 2026,” Jordan said. “As we build on this progress, we remain focused on maintaining a robust balance sheet while completing the refinancing of our senior secured notes due December 2026.”

Curaleaf shares traded 5.26% lower at $2.52 per share at the time of writing Tuesday.

Aurora Locks In Exclusive EU Commercialization For Top Genetics

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) strengthened its European portfolio after securing EU-wide plant variety rights for two of its leading medical cannabis strains, granting exclusive commercialization across the European Union’s 27 member states.

“Being granted Community Plant Variety Rights in the EU is a direct recognition of the exceptional cannabis genetics work underway at our preeminent Aurora Coast R&D facility,” said Lana Culley, vice president of innovation and international operations.

The Cannabis sativa L. varieties, SOT20R07-007 and ACB21T044 (marketed as Farm Gas and Sourdough), were bred in Canada through Aurora’s advanced breeding and phenotyping programs. They are currently core products for medical patients in Germany, Poland, the U.K., Canada and Australia.

Aurora shares traded 3.36% lower at $4.09 per share at the time of writing Tuesday.

Medipharm Names Interim CEO As It Expands Into Latin America

MediPharm Labs (TSX: LABS) (OTCMKTS: MEDIF) (FRA: MLZ) announced Monday that CEO David Pidduck will step down effective Friday, Jan. 23, 2026.

The leadership transition follows Medipharm’s entry into Latin America through a Costa Rican supply agreement that allows the company to ship medicinal cannabis products to a subsidiary of Remidose Aerosols in the region.

The company’s board appointed CFO Greg Hunter as interim CEO. Hunter has served as chief financial officer since February 2021 and brings more than 20 years of leadership experience across finance, sales, marketing and operations at Fortune 500 companies and private equity-backed firms.

Medipharm shares traded 0.18% higher at $0.0547 per share at the time of writing Tuesday.